Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
May 8, 2026
What were the key takeaways from Vaxart, Inc.'s May 8, 2026 earnings call?
In Q1 2026, Vaxart, Inc. reported a significant revenue increase to $39.2 million, up from $20.9 million in the same quarter last year, primarily driven by a BARDA contract. The company achieved a net income of $5.2 million, or $0.02 per share, reflecting effective cost management. Management maintained guidance for a cash runway extending into Q2 2027, emphasizing ongoing clinical milestones and operational efficiency as key drivers for future growth.
What topics did Vaxart, Inc. cover?
- Revenue Growth: Vaxart's revenue for Q1 2026 reached $39.2 million, a substantial increase from $20.9 million in Q1 2025, driven largely by the BARDA contract. Management stated, "The growth in revenue was primarily driven by BARDA contract," highlighting the importance of government partnerships.
- Clinical Trial Updates: The Phase IIb COVID-19 trial's sentinel cohort is nearing completion, with management emphasizing that the primary focus is on safety and immunogenicity rather than efficacy. Dr. Cummings noted, "This cohort was not powered to provide a statistically significant comparison between the oral pill and mRNA vaccine groups," indicating a cautious approach to data interpretation.
- Operational Efficiency: Vaxart has streamlined operations and reduced expenses, which contributed to a net income of $5.2 million for the quarter. CFO Jeroen Grasman stated, "We reduced our R&D and G&A expenses compared to the first quarter of 2025 by closely managing personnel and facilities costs," showcasing effective cost control.
- Board Enhancements: The addition of Dr. James Breitmeyer to the Board is aimed at strengthening clinical and regulatory oversight as Vaxart approaches critical data milestones. CEO Steve Lo remarked, "His experience and track record... provides us with a distinct advantage," indicating a strategic move to enhance governance.
- Funding and Financial Flexibility: Vaxart established a $25 million share purchase agreement with Lincoln Park Capital to enhance financial flexibility. Grasman explained, "This facility provides us with an efficient capital management tool that we can utilize to support our capital needs at our discretion over the next 24 months," indicating proactive financial management.
What were Vaxart, Inc.'s May 8, 2026 results?
- Revenue: $39.2 million (vs $20.9 million last year, +87% YoY)
- Net Income: $5.2 million (vs $2.5 million last year, +108% YoY)
- EPS: $0.02 (vs $0.01 last year, +100% YoY)
- Cash Position: $61 million (vs $50 million last quarter, +22% QoQ)
- Cash Runway: Into Q2 2027 (Maintained guidance)
- R&D Expenses: Reduced (Compared to Q1 2025)
Vaxart's strong revenue growth and effective cost management position it favorably for future developments, particularly as it approaches critical clinical milestones. However, the delays in data release and funding for the norovirus program present risks that investors should monitor closely. The upcoming data readouts and potential partnerships will be key catalysts for stock performance.
Earnings Call Speaker Segments
David Carey
executiveAppreciate that, operator. Hello, everyone, and thank you for being here on today's call. Joining us from Vaxart are Chief Executive Officer Steve Lo; Dr. Sean Tucker, our Founder and Chief Scientific Officer; Chief Medical Officer Dr. James Cummings; Chief Financial Officer Jeroen Grasman; and Ed Berg, Senior Vice President and General Counsel. Before we begin, please keep in mind that during this conference call, forward-looking statements may be made by Vaxart. This covers things like the company's numbers and its guidance, how it plans to run and grow the business going forward, deals it may strike with outside parties, when it expects regulators to sign off (or whether that sign-off happens at all), how long its cash will last, whether it can get back into good standing with NASDAQ's listing rules or bring in money once that standing returns, plus how it develops products and moves them through the regulatory pipeline — that includes what it says about trials now underway or on the drawing board. What we actually see down the road might end up looking quite different from what these forward-looking statements suggest, and that's because several significant elements come into play — among them the unpredictable nature of drug testing and the approval pathway, plus additional dangers spelled out under the Risk Factors heading in Vaxart's latest yearly filing on Form 10-K, as well as in other routine reports the company submits to the SEC. Vaxart isn't committing to revise any forward-looking statements once this call has taken place. At this point I'll pass the floor to Steven Lo. Steve?
Steve Lo
executiveAppreciate that, David. Hello, everyone, and thanks for being here this afternoon. During Q1, we achieved significant strides in moving our clinical programs forward and getting ready for critical data milestones that, in our view, will showcase the worth of our oral vaccine platform. Along with getting our COVID-19 program ready for the readout ahead, we've devoted recent months to bolstering our financial standing and making our operations more efficient, which supports disciplined execution and lengthens our runway. More precisely, our Q1 efforts centered on the actions required to reveal findings from the 400-person sentinel cohort within our Phase IIb COVID-19 study. This group plays a vital role in our program, giving us our initial 12-month assessment of safety, certain efficacy metrics and the immune response as well of our oral vaccine candidate in a head-to-head investigation. Right now we're navigating the data reconciliation work needed to finish the analysis and progress toward a top line readout; our partners at BARDA are strongly committed to backing this effort. In order to reinforce our Board and bring in clinical and strategic oversight, we were glad to add Dr. James Breitmeyer to our Board of Directors during April. Jim is a seasoned drug development expert who has guided numerous candidates through intricate clinical and regulatory journeys. His biopharmaceutical experience spans over 35 years, encompassing leadership of programs that led to several FDA approvals and regulatory wins worldwide. As part of our continued dedication to refreshing the Board, alongside bringing in Dr. Breitmeyer, we've welcomed two additional directors possessing substantial drug and business development know-how within the last two years, which strengthens things by contributing fresh viewpoints. In our view, bringing on directors with such demonstrated histories is a major benefit as we get closer to our forthcoming data catalysts. When it comes to operations, we finished relocating our headquarters in April, combining and shrinking our space, and we also set up a $25 million share purchase agreement with Lincoln Park Capital. Not a single share has been sold so far, and any use of this purchase agreement remains at the company's discretion. Such measures form part of our sustained push to keep operations lean, deliver financial flexibility and put us in position to steer our capital toward our primary drug development programs. Lastly, we're still engaged in constructive conversations with the team at Sanofi as we push our COVID-19 program forward. I'll now hand things over to James to bring you up to speed on the status of the COVID-19 trial. James?
James Cummings
executiveAppreciate that, Steve. The main objective for our Phase IIb COVID-19 study is to assess how safe and effective our oral vaccine pill is when measured against the top injectable mRNA vaccines. Never before has our mucosal technology undergone clinical testing in a direct, head-to-head comparison with an approved mRNA benchmark, and that represents a major milestone for our platform. Our first glimpse at this side-by-side evaluation is drawn from the 400-person sentinel cohort. Right now, we're in the last administrative phase of validating data and reconciling quality for that group. Let me be completely straightforward about where we stand. At Vaxart, management remains blinded to the findings and hasn't examined the data. That's standard practice, making sure the analyses are locked down before results get unblinded and shared following the process we agreed upon with BARDA, the group funding us. Since BARDA funds this study, partnership protocols and data sharing procedures are in place that dictate how our unblinding happens; these represent intentional, standard administrative steps that are necessary when a government partner is involved. At present, we're finishing those last steps alongside BARDA to enable the release of top line results. Keep in mind that the main reason for this sentinel cohort is assessing safety along with immunogenicity, which includes follow-up over a longer term. Although certain efficacy related measures will be reported, this 400-person sentinel cohort lacked the power to deliver a statistically significant comparison between the oral pill and mRNA vaccine groups. Back in January of 2025, we announced that an independent Data Safety Monitoring Board, or DSMB, had already performed a planned review of the initial safety data from this cohort and advised that the study proceed with no changes. That gave us valuable external validation regarding our platform's safety, even as we at Vaxart stay blinded to the complete 12-month data. These results serve as a meaningful precursor to how our oral pill vaccine stacks up against mRNA vaccines, yet as noted, this cohort lacked the power to deliver a definitive efficacy comparison. Stronger, more conclusive insights should emerge from our main cohort of roughly 5,000 participants, which is built and powered to assess relative efficacy and safety. I'll hand the call over now to Sean Tucker for a discussion of norovirus. Sean?
Sean Tucker
executiveThanks, James. Right now, we're assessing how our second-generation constructs stack up against the GII.17 norovirus strain. That strain has grown far more dominant, so we're running tests on the cross-neutralization abilities of our bivalent vaccines to confirm they can identify and counteract this newly emerging variant. We anticipate presenting those preclinical findings and incorporating clinical assessments into the final study later in this year, at both scientific conferences and possibly in scientific journals. As for what comes next with norovirus, we're ready to launch our following clinical trial in 2026, contingent on ownership or securing additional funding. In the interim, we keep honing our vast platform alongside our manufacturing operations so that our high-yield tableting stands ready for large-scale demand. I'll pass the call to Jeroen now for the financial portion. Jeroen?
Jeroen Grasman
executiveThanks, Sean. At the close of Q1, Vaxart held $61 million across cash, cash equivalents, and short-term investments. First-quarter revenue came in at $39.2 million, up from $20.9 million a year earlier, and that increase was mainly attributable to the BARDA contract. Revenue recognized under the Dynavax license and collaboration agreement, which was signed in November 2025, also contributed to Q1 2026. On top of that, by keeping tight control over personnel and facilities costs, we brought down both R&D and G&A expenses relative to Q1 2025. Those two factors — revenue growth and cost discipline — produced net income of $5.2 million, or $0.02 per share, for the quarter. As Steve noted, we strengthened our financial flexibility in April by putting in place a $25 million share purchase agreement with Lincoln Park Capital; this facility gives us an efficient capital management tool that we can draw on at our discretion to meet capital needs over the coming 24 months. Under our current plan, we still anticipate that our cash runway will reach into Q2 2027. Now that this quarter's move is done and the lease termination kicks in next week, our long-term liabilities and fixed overhead have been substantially lowered, which lets us direct resources toward our clinical catalysts. We're ready for your questions.
David Carey
executiveWe've gotten a large number of inquiries from lots of shareholders, and quite a few of them overlapped. So to start, we're putting the questions together according to subject. The first one: many people have been asking about what the main emphasis of the sentinel readout is, and whether that emphasis is safety rather than efficacy; also, questions about whether folks can still expect that readout, since early Q2 has already gone by. I'll hand that one over to James. James?
James Cummings
executiveApologies, I got caught on mute there. Thank you, David. Just to remind everyone, the main reason this sentinel cohort exists is to assess safety and immunogenicity, which includes follow-up over a longer period. Evaluating efficacy has never been its purpose, nor is it now. Some efficacy-related measurements will be reported, yes, but what this 400-person sentinel cohort was set up to deliver — and this is the key point — is a comparison between the oral pill and mRNA vaccine groups that carries statistical significance. Back on January 25, we announced that an independent data safety monitoring board had already completed a scheduled review of the initial safety data from this cohort, and its recommendation was that the study proceed with no changes. The DSMB has kept meeting and has reconfirmed those conclusions. That gives us valuable external validation of our platform's safety, even though we stay blinded to the complete 12-month data. These results matter as an early signal of how our oral pill vaccine stacks up against mRNA vaccines, but as I said, this smaller cohort lacked the power to deliver a definitive efficacy comparison. The reason is that with 400 people, it simply wouldn't be powered specifically to arrive at that conclusion. The point is to gather sufficient data so false negatives are avoided and so results can't be attributed to chance. More conclusive insights, however, should emerge from our main cohort — roughly 5,000 participants in this study — which has been designed and powered to assess relative efficacy along with safety. Beyond that, we're putting substantial resources behind running the 5,000-participant main study cohort, which stands as a central focus of our clinical efforts. We expect the primary efficacy and safety data readout from that larger group in early 2027. I believe that covers it, David.
David Carey
executiveAlright, thanks James. The following question is also directed at you. Is it Vaxart's view that there will be a significant distinction when it comes to immunogenicity, longevity, and cross-reactivity of the immune response, as well as viral — apologies, better load reduction, that could be observed even within a small cohort?
James Cummings
executiveThanks, David. I won't be rushing to any judgments or setting any results in stone at this point; the data remains blinded to us. As soon as it's unblinded, we'll review it against the right context.
David Carey
executiveAppreciate that, James. Here's one more thing I'd like to ask you. When it comes to getting the sentinel cohort data out, what exactly remains outstanding on the part of both Vaxart and BARDA?
James Cummings
executiveLike I said before, right now we're at the last administrative step for this group — validating the data and reconciling quality. That's fairly typical. During this step, the data gets a careful review to make sure it's accurate, complete, and consistent before analysis — again, normal for a study this large and this important. What that means is an outside party is going over the database to confirm entries were made correctly and to flag any records that may be incomplete. The purpose is to guarantee the final analysis rests on the most accurate data we can get. We're collaborating closely with our partners at BARDA to finish these steps so the sentinel cohort data can be released. To be clear, though, this is about procedure; it isn't a problem with the data. The study is still blinded, and we ourselves haven't seen the results yet.
David Carey
executiveAppreciate that, James. The following question has come in from a number of people, and it also showed up on the web portal this afternoon. What caused the schedule to move out? Do you have confidence that the data will come out prior to the quarter's close?
James Cummings
executiveThat's a legitimate question. The third-party review is running behind what we expected, because there are quite specific partnership protocols and contractual guidelines around data sharing that govern the timing of our unwinding. When you're dealing with a contractual partner, these are deliberate administrative steps that have to happen. All of this is taking much more time than we had hoped. We're in the middle of those final steps right now. We're still targeting the top line results for Q2, but it's important to keep in mind that we're dealing with the contractual part of a partner, and that timing isn't fully within our control. That's my projection.
David Carey
executiveAll right. James, could you share more specifics about what BARDA has asked Vaxart for, which has led to a hold-up in putting out your safety data?
James Cummings
executiveAbsolutely. So within this partnership, BARDA is collaborating alongside us to lock down the analysis plan and make sure every pertinent data element gets folded in for that sentinel cohort I brought up earlier. That covers going over certain details normally handled at a later point in the study, yet right now they're being added so the analysis process stays thorough and aligned. We keep working hand in hand to finish these steps and make certain the data are completely validated and set for disclosure.
David Carey
executiveAppreciate that, James. Let's take the next question. With the sentinel cohort's results reporting pushed back, should we read that as a sign something is wrong — either with the data itself, or with how it's being gathered or examined.
James Cummings
executiveIt's beginning to feel like the James program. And no, that isn't the case. What we're dealing with here is a standard part of how data gets analyzed and shared; it has nothing to do with the data itself, how it was gathered, or how it was analyzed. There were particular rules set by our government partner that determine the timing and method for unblinding blinded data and sharing it. Completing those steps has taken more time than we expected at the outset, though they're procedural by nature. Right now, everyone at Vaxart Management remains blinded to the results, and we haven't laid eyes on the data. As soon as the administrative green light comes through, we'll turn that card face up, unblind everything, and report — me included; we're eager to do that, just as you are.
David Carey
executiveAll right, thanks, James. Moving on to norovirus now. For the next question: has there been any additional dialogue with the partners you're considering regarding the norovirus program? And do you see a realistic possibility that a funding partner could be brought on board for norovirus prior to the close of this year — Steve, I'll direct that one to you.
Steve Lo
executiveAbsolutely. Talks with prospective partners are still ongoing, and I want everyone to know this is something we remain focused on. That said, as you'd imagine, there's no way for us to promise a deal will get done or say when one might happen—but I can tell you we're at it nonstop to keep those conversations productive and moving. Our team is fully committed to this and believes in it strongly. And honestly, getting the money in place for this trial is an essential next move for the business, and that's exactly how we're approaching it.
David Carey
executiveAll right, Steve. The following question we have is: how probable is it that a Phase IIb norovirus study gets underway during Q3? And Steve, would you handle that one?
Steve Lo
executiveYeah. We get that what you're asking about is speed. So give me a moment to walk through how we think about this, okay? Funding ends up being the constraint here. It isn't the science. We've pointed that out, and you've likely noticed that pushing the norovirus program ahead matters to us for the next clinical stage, and that truly hinges on landing a partnership or bringing in outside funding; as I mentioned before, we're in conversations with possible partners. We're evaluating a range of alternatives, and our intent is to advance this in a highly strategic way that uses capital efficiently. Bankrolling this takes substantial resources, so aligning the program with the proper partner and the proper funding structure to back its success is essential. That's because we aim to be responsible stewards of shareholder capital; we won't hurry into a trial that ends up underpowered or poorly designed simply to check off a milestone.
David Carey
executiveThanks, Steve. Moving on to the next question. Sean, would you mind handling this one? Has there been any interest from BARDA regarding norovirus or flu? Given their focus on next-generation platforms, it appears that Vaxart is in a distinct position to collaborate with them in order to bring those products to market.
Sean Tucker
executiveAbsolutely. As everyone knows, we maintain an active and fruitful partnership with BARDA tied to our COVID-19 initiative. Beyond that, we also worked with them previously on flu, so our platform and the wider range of things we can do are quite well known to them. Right now, BARDA's backing centers on the ongoing COVID study, and no further funding has been disclosed from BARDA for either the norovirus or the flu programs. We'll keep assessing various possible sources of funding, among them government entities and strategic partners, in order to move every one of our programs forward.
David Carey
executiveAppreciate that, Sean. Before you kick off the NORA Phase II, do you think you can bring about VX20 and/or VX22 antibodies in most subjects? Sean, would you handle that question?
Sean Tucker
executiveYeah, that's a good question. So VX20 and VX-22 are monoclonal antibodies that neutralize broadly and react across a wide range of genotypes. It's worth remembering that these antibodies were cloned from participants in a Vaxart clinical trial. That said, those clones might not work for everyone, since people have different genetic backgrounds. So because of that, our focus is on pushing forward norovirus programs that can serve all people, regardless of genetic background. The important takeaway here is that what we're doing right now is far more proactive and relevant — for example, we're testing how well our bivalent vaccine cross-neutralizes the GII.17 norovirus strain, which has lately turned into a more common variant around the world.
David Carey
executiveAppreciate that, Sean. Let's move to the next question. Is there anything you can share about where things stand with Sanofi? Do you have confidence that Sanofi is going to keep up the collaboration that you set up with Dynavax? Steve, would you mind handling that one?
Steve Lo
executiveOkay, just to remind everyone, Dynavax is now part of Sanofi — that deal wrapped up during Q1. So from here on, I'll mostly be talking about this collaboration as Sanofi. And I definitely want all of you to know that we keep having — and we maintain — a really strong, productive dialogue with the folks at Sanofi as we push the COVID-19 program ahead; they're with us in believing that worldwide need for COVID-19 vaccines is still strong. And just to remind everybody, our exclusive license and collaboration agreement with Sanofi covers the entire world. Only after Sanofi reviews the data from the Phase IIb clinical trial and completes the end-of-Phase IIb meeting with the FDA does Sanofi have the option to take on full responsibility for the program. Since BARDA is funding this ongoing trial to a large degree, as we've talked about before, our colleagues at Sanofi clearly view this as getting access to a high-value clinical data trial that government investment has substantially derisked.
David Carey
executiveAppreciate that, Steve. Moving on to the next question: is there anything new regarding where things stand with the avian influenza study, or any sense of when those results could become available to investors? Sean, would you handle that one?
Sean Tucker
executiveCorrect. Once more, what we're aiming for is getting this data out through a peer-reviewed journal. And once more, when that happens hinges on how that process goes. Just like with our other programs, we'll definitely share updates when it makes sense and after that process wraps up.
David Carey
executiveAll right. Moving on to the following question: what's the reasoning behind entering into a share purchase agreement right now, considering that the company's cash runway reaches into Q2 of 2027? And Jeroen, would you mind taking that one?
Jeroen Grasman
executiveAbsolutely. Thanks, David. This deal lets us bolster the balance sheet when we need to, entirely at our own discretion. So we can act at any moment throughout the agreement's 24-month term; we keep complete say over when and how much we sell, since LinkoPark must buy the shares whenever we direct. There's potential for this arrangement to deliver wider advantages for the company too. Take, for instance, how a backstop financing facility can give us more leverage in partnership talks, given that we have additional access to capital. And when a high-value investment opportunity comes along, we're able to move fast without the delay and cost of a conventional capital raise. Over to you, David.
David Carey
executiveAppreciate that, Jeroen. The following question is also directed your way. Is there a particular purpose Vaxart intends to put that extra funding toward?
Sean Tucker
executiveOkay, so to begin with, like I mentioned earlier, this share purchase agreement gives us both financial flexibility and optionality on terms that are favorable when compared with the more traditional rates. That's why we're using it. As a result, whatever proceeds get used will be decided by what our particular needs happen to be at the moment of the sale. According to what our disclosures have said, the money is meant for working capital as well as general corporate purposes. Clearly, the aim here would be to back the priorities we already have. That covers moving forward our norovirus proband, which is leading the collations currently underway, plus other programs, and developing our pipeline, including the avian flu programs and additional vaccine candidates, which we discussed just now. Either way, the proceeds would be used to genuinely fund activities that create value, rather than simply to prolong our runway. David?
David Carey
executiveAppreciate that, Jeroen. Our following question comes from Steve. Could you walk us through why it makes sense to add Dr. Breitmeyer to the board right now? And do you have any additional board changes in the works?
Steve Lo
executiveDr. James Breitmeyer brings strong credentials as a pharmaceutical executive. He knows what it's like to sit on a board. His clinical and regulatory background stretches across 35 years. As we moved toward several key data milestones that matter greatly to us — clearly this includes the readouts coming up for our COVID-1 program, which BARDA funds — Jim's background, plus his history of steering programs all the way to 8 FDA product approvals, gives us a real edge. Beyond that earlier work, he also held the role of President at Bavarian Nordic, a vaccine company. While there, he was in charge of developing vaccines for infectious disease and bioterrorism. That fits exactly with what we're doing together with our government partners. So this is why we feel Jim's know-how is genuinely assisting us in steering along this complicated route from clinical development through to regulatory approval, and it will prove invaluable as we proceed with validating our oral vaccine platform.
David Carey
executiveAll right. Steve, I've got one more thing to ask you. Is there anyone on Vaxart's board of directors who intends to resign, or are you in the process of adding members to the Board?
Steve Lo
executiveWe consistently assess the makeup of our board and the skills currently represented, to make sure we've got the right expertise backing the company's strategy and our stage of development; with the recent additions, we think the Board accomplishes exactly that, correct? The recent appointment of Dr. Breitmeyer showed that our priority is bolstering capabilities in fields such as clinical development and regulatory strategy. And moreover, reflecting our continued dedication to refreshing the Board through the addition of Dr. Breitmeyer, keep in mind that we have brought on 2 new directors within 2 years who possess considerable drug and business development expertise, and that truly guarantees we have new viewpoints on the board.
David Carey
executiveAll right, a couple more things from the Board. Steve, you're up next. Could you walk us through why the board changes happened recently, and how those moves line up with what shareholders want? Also, would you be open to adding someone who represents retail shareholders to the Board?
Steve Lo
executiveRight. The Board feels that regularly injecting pertinent new viewpoints into the boardroom matters a great deal. And naturally, directors must also deliver stringent supervision when it comes to carrying out our strategy; thus their expertise and backgrounds are essential for that. What's more, the latest shifts in board composition demonstrate a commitment to making sure we possess the proper blend of know-how to back the company at its present stage and in light of its priorities. That also means bolstering strengths in fields such as clinical development, regulatory strategy, capital markets; these matter for a business like Vaxart as we move our programs forward. And such choices line up with shareholder interests by putting the company in position to execute well and capture the greatest value from our platform and pipeline. As we have demonstrated, the Board welcomes new viewpoints and would review and assess any suitably qualified nominee through the Board's nominating and governance committee process.
David Carey
executiveAlright. Let's take the next question. What reason is there for shareholders to trust that the present Board, along with any newly proposed directors, will generate value moving forward? Steve?
Steve Lo
executiveTo reiterate what I mentioned before, the Board is closely monitoring our strategy, the way we deploy capital, and the headway we're achieving. They collaborate intently with the leadership group and keep every one of us on the management side answerable for delivering; by doing that, they position this company as favorably as possible to boost shareholder value. Like I said previously, correct, we brought on 2 additional directors, and they supply the appropriate blend of medical, business, financial, and other pertinent background, plus know-how, to propel our company ahead and likewise guarantee we possess the cash runway needed to carry out our strategy. To be specific, our Board gains from our directors' extensive variety of backgrounds spanning clinical development, regulatory strategy, commercialization, business development among numerous fields, and that lines up directly with moving our pipeline forward.
David Carey
executiveAppreciate it. Steve, in your view, what part ought shareholders to play when it comes to picking members of the Board of Directors?
Steve Lo
executiveRight. Every investor, regardless of whether their stake is large or tiny, gets to be heard. During the annual meeting process, their ballot counts. Members of our Board of Directors and our management team hold shares too, so what matters to all Vaxart investors matters to us. Shareholders ought to understand that our directors are dedicated to building value and to doing what serves the interests of every Vaxart shareholder best. They supervise a well-defined plan to move our programs forward, fuel growth, and lengthen our runway, so that in the end, we can generate value for shareholders.
David Carey
executiveAlright. Thank you. Steve, I have one more thing to ask you. Over the next 12 months, how are you going to earn investors' confidence and boost shareholder value with urgency?
Steve Lo
executiveAbsolutely. So the number one thing for us is hitting those important clinical milestones — the sentinel readout we talked about, plus the fully powered Phase IIb data coming later this year — since we see those as the biggest value drivers. We're concentrating on executing with discipline and managing costs, just as we laid out before, making sure resources go to the programs with the greatest impact, and at the same time keeping our runway intact. And last, our aim is to move our clinical programs forward. So, like I said before, we want to produce meaningful data and use those results to back partnership opportunities and the wider value of our platform.
David Carey
executiveAll right, thanks. Steve, we'll take the following question. In your view, is a rise in the share price over the near term something you treat as a priority? And how do you weigh that against the strategy you're pursuing for the longer term?
Steve Lo
executiveAbsolutely. Our Board and management team never lose sight of building shareholder value both right now and down the road. We have confidence that the moves we are making at present to push our pipeline forward, while at the same time lengthening our run — runway, will generate the greatest value for shareholders over the long term. Simultaneously, we understand how much near-term value creation matters, and we think we can achieve that through those very same drivers that will produce durable long-term value. So it comes back to the science, securing favorable results for patients, carrying out our growth strategies, and reaching the strategic outcomes we have been discussing.
David Carey
executiveAll right, thanks. Jeroen, here's the next one for you. Some folks are asking about how management weighs the risk of dilution against keeping flexibility intact; and it's also common knowledge that people have raised the question of when we'd look at bringing in capital as opposed to depending on funding from partnerships?
Jeroen Grasman
executiveThanks, David. When it comes to how we deploy capital, the aim is striking a balance between staying disciplined on spend and pushing our science forward, all so the business ends up in a stronger strategic and financial position down the road. To get there, we require enough cash runway to carry out the buildup of our vaccine portfolio as time goes on. That's why we went after, and keep going after, funding that doesn't dilute shareholders plus partnerships — you can see that in BARDA's continuing backing and in our Dynavax collaboration, both of which have brought real validation and money. The deal we struck most recently with Lincoln Park Capital is yet another solid illustration of how we approach raising capital, and the idea is to give us access to funds when needed instead of forcing us to bring in a lump sum in one shot. On top of that, we're clear-eyed that other routes to bringing in cash are necessary if we're going to hit the results we want and, in the end, drive shareholder value as high as possible. That's all I've got.
David Carey
executiveAppreciate that, Jeroen. Thanks a lot. Steve, the following question is headed your way. How do you intend to get back into compliance and return to listing on NASDAQ, and what's the timeline for that? Also, to make that happen, would it take a reverse stock split?
Steve Lo
executiveWe're concentrating on carrying out our strategy and moving our clinical programs forward, and our intention is to keep that as our focus; in our view, that will be the main thing driving value over the long term. Also, we do evaluate, and will keep evaluating, what the optimal path looks like given market conditions and how far the company has come. So our aim is genuinely to act in the shareholders' best interest here; therefore it really comes down to carrying out our strategy and moving our clinical programs forward.
David Carey
executiveAll right. Thanks, Steve. Now we move on to a set of questions about the proxy and the annual meeting; Ed, would you handle the first one — what's the timing for filing your proxy statement?
Ed Berg
executiveAbsolutely. So in the near future, we'll be giving those who hold our stock an update regarding the yearly gathering, and naturally, that information will be shared via our proxy documents. Also, as is the case with every publicly traded business, we hold a meeting for shareholders annually, and they can expect to learn additional details about it going forward.
David Carey
executiveAlright. Thanks; and I've got a couple additional questions for you on this subject. Have you had any discussions with that shareholder group that's involved?
Ed Berg
executiveWe consistently interact with a wide variety of shareholders, and dialogue along with their input is something we welcome, yet we won't discuss particular discussions. Listening to what shareholders think remains our commitment, taking those views into account in the ordinary run of things and keeping channels of communication open.
David Carey
executiveHas that shareholder group, which is concerned, given Vaxart any notice of plans to put forward Board nominees? Any nominations come in to you?
Ed Berg
executiveAs I mentioned, we don't discuss particular communications from shareholders or speculate about steps we might take. That said, whenever disclosure duties apply, we certainly treat them as important. So if there's anything requiring disclosure, we'll handle it in the proper manner. The group of Director candidates we're putting forward is going to appear in the proxy, and that document will be submitted within the next few weeks.
David Carey
executiveAll right, a subsequent inquiry. What date served as the cutoff for that worried investor coalition to put forward its candidate slate for board seats?
Ed Berg
executiveThe period during which we accepted director nominations ran from February 2, 2026 through March 4, 2026, meaning it is now shut. And naturally, I'd ask all of you to keep watching for our proxy filing.
David Carey
executiveAll right. Thanks, Ed. Taking a look at the Q&A portal, it appears every question that came in has been — those submitted have all been addressed, and nothing new has come our way. So, Steve, I'll hand the call back to you for your closing remarks.
Steve Lo
executiveAlright, David, thank you. I'd like to express gratitude to each of you for being here and for sending in your questions. The level of involvement from everyone who holds shares with us means a lot. Right now is a pivotal and thrilling moment for Vaxart. Our programs are moving forward. We're very close to putting out data, and we're making careful moves to lengthen our financial runway so that we have both the adaptability and the means to carry out the plan we're currently pursuing. Our dedication stands firm when it comes to developing oral pill vaccines that are safe, effective, and accessible — ones that safeguard communities around the world and assist individuals in living healthier lives; by doing this, we feel certain we can build shareholder value that lasts. Once more, thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.